Avanzanite Bioscience Partners With Advicenne to Commercialize Sibnayal ® For the Treatment of Rare Kidney Disease in Germany, Austria, Switzerland and Greece
Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”), a specialty pharmaceutical company offering end-to-end commercialization and distribution partnerships with research-based biopharmaceutical originators, announced today that it has signed an exclusive distribution agreement with Paris-based specialty pharmaceutical company Advicenne for a medicinal product approved by the European Commission for the treatment of distal Renal Tubular Acidosis (dRTA).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005029/en/
Adam Plich, CEO & Founder (Photo: Business Wire)
Avanzanite’s Founder and CEO, Adam Plich, stated, “Today’s announcement is in lock-step with our purpose – both ethical and economic – of delivering novel medicines to patients suffering from rare diseases into markets across Europe and unlocking revenue potential for Advicenne.” Mr. Plich continued, “Since our formal corporate launch just a couple months ago, today’s announcement with Advicenne further validates our unique business model. With this partnership, we are now safely moving beyond platform validation, into a phase of execution and gaining critical mass through pipeline expansion.”
dRTA is a rare and serious kidney disease in which acid builds up in the blood. This leads to a range of symptoms including hearing loss and stunted growth in children, as well as vomiting, kidney stones and lack of alertness. The disease also causes levels of potassium in the blood to fall, which can lead to muscle weakness and paralysis.
“We too are on a mission of delivering this important new medicine to as many dRTA patients across Europe as possible,” stated Didier Laurens, Chief Executive Officer of Advicenne. “We consider that Avanzanite’s business model is tailor made for companies like Advicenne and will surely help us successfully commercialize our product in European markets where it would have taken time to build expertise with regard to pricing and reimbursement, physician engagement and distribution footprint,” Mr. Laurens concluded.
Avanzanite is advancing discussions with several other biopharmaceutical companies seeking to enter the European market to expand its portfolio breadth. Given the high number of investigational drugs in development for rare diseases, Avanzanite envisions significant opportunity to expand patient access and optimize value creation for originators. Avanzanite sees its near-term growth opportunity in late-stage or approved ultra- or other overlooked orphan medicines. Mr. Plich concluded, “We’ve cracked the code in deciphering this tricky landscape, and now, with Advicenne as a partner, in addition to our initial strategic partnership with SIFI, we are ready to take our transformational model to the next level by bringing new medicines to patients with rare diseases.”
ABOUT AVANZANITE BIOSCIENCE: Avanzanite is a commercial-stage pharmaceutical company on a mission to redefine the commercialization of orphan medicines to improve patient access across Europe and beyond. Derived from the word ‘Tanzanite’ – one of the rarest and most underappreciated gemstones on earth – Avanzanite was formed to capitalize on two primary objectives, one economic, and one humanitarian. The economic goal is to offer end-to-end commercialization and distribution partnerships to research-based biopharmaceutical originators to unlock the full value of their orphan medicines in European markets; this is the unique expertise and core competency of the Avanzanite team through its decades of operating experience navigating this area. Equally important, the Company's humanitarian goal stems from its commitment to enabling access to novel medicines for patients who suffer from orphan diseases regardless of where in Europe they live. Go to www.avanzanite.com for additional information.
ABOUT ADVICENNE. Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product (ADV 7103) has received its Marketing Approval for distal renal tubular acidosis in EU and the UK. ADV 7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information see: www.advicenne.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005029/en/
Contact information
Avanzanite Bioscience B.V.
+31 20 301 21 13
investors@avanzanite.com
media@avanzanite.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO ® (avelumab)27.3.2023 14:00:00 CEST | Press release
Merck today announced it has strengthened its Oncology franchise by regaining exclusive worldwide rights to develop, manufacture, and commercialize anti-programmed death ligand-1 (PD-L1) antibody BAVENCIO® (avelumab) following the termination of their Alliance agreement with Pfizer. “On behalf of Merck, I’d like to thank Pfizer for their partnership and collaboration over the last nine years, and for the role they have played in the success of BAVENCIO,” said Belén Garijo, Chair of the Executive Board and CEO of Merck. “Our joint efforts have delivered meaningful therapeutic value to patients around the world who are living with cancer. This has been an incredible journey for us, and thanks to Pfizer’s partnership we are now very well positioned to continue to deliver this therapy to patients in need.” “Our alliance with Merck allowed us to combine our complementary strengths to develop and launch BAVENCIO to help meet the needs of people with cancer globally,” said Dr. Albert Bourla,
Ecoppia Expands its Global Presence with 4 New Projects in Spain and Chile with Matrix Renewables27.3.2023 14:00:00 CEST | Press release
Ecoppia, world’s leader in robotic cleaning solutions has announced an agreement to deploy its robotic solutions in 4 projects developed by Matrix Renewables, the TPG Rise-backed global renewable energy platform. This collaboration will mark Ecoppia’s first project in the Spanish region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230327005227/en/ Ecoppia H4 Autonomous Robotic Cleaning Solution (Photo: Business Wire) Ecoppia will deploy two robotic models at these PV sites – the Ecoppia H4 and the Ecoppia T4. Both robots are water-free and perform highly efficient cleaning while proven to be fully safe on the modules and structure. Ecoppia will also provide the operations and maintenance (O&M) to the robotics fleet for the projects’ lifetime. The expected total revenues from these projects during their lifespan is estimated at around $13M USD, of which $3.9M against the systems delivery and installation. This announcement
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes27.3.2023 14:00:00 CEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230324005339/en/ “We have multiple programs in our T1D portfolio including VX-880 and VX-264, which are in the clinic, as well as our hypoimmune program, in preclinical development,” said Bastiano Sanna, Ph.D., Executive Vice President and Chief of Cell and Genetic Therapies at Vertex. “Having successfully demonstrated clinical proof of concept in T1D in our VX-880 program, we are excited to deepen our relationship with CRISPR Therapeutics with this agreement, which will allow us to further accelerate our goal of generating fully dif
Enviva Issues Statement Following Destructive Storms and Tornadoes in Mississippi27.3.2023 13:00:00 CEST | Press release
Enviva Inc. (NYSE: EVA) (“Enviva,” the “Company,” “we,” “us,” or “our”), the world’s leading producer of sustainably sourced woody biomass, reported that all of its associates are safe and accounted for following a strong tornado that touched down in Amory, Mississippi, on March 24, 2023. The storm did, however, damage the Company’s 115,000 metric ton per year wood pellet production facility, although Enviva’s larger plants and ports in the region were not impacted. Enviva’s Amory facility insurance covers property damage, inclusive of business interruption and casualty. Operations at the plant have been suspended pending a full review of the damage, but given the small size of the facility relative to the more than six million metric tons of installed production capacity across the Company’s portfolio, the impact to customers and to the financial performance of the Company is expected to be minimal. “Amory was our very first plant in the Southeast U.S. and this community holds a speci
Li-Cycle and KION Group Form Strategic Global Lithium-Ion Battery Recycling Partnership; Li-Cycle Announces New Spoke Development in France27.3.2023 12:00:00 CEST | Press release
Li-Cycle Holdings Corp. (NYSE: LICY) (“Li-Cycle” or the “Company”), an industry leader in lithium-ion battery resource recovery and the leading lithium-ion battery recycler in North America, has signed a definitive agreement (“agreement”) for a global lithium-ion battery recycling partnership with the KION Group (“KION”), a leading global provider of industrial trucks and supply chain solutions. The Company is also pleased to announce plans to develop a new lithium-ion battery recycling facility in France, underpinned by regional commercial demand, including KION’s lithium-ion battery recycling needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230327005333/en/ Strategic Partnership for sustainable circular economy: Andreas Krinninger, member of the Executive Board of KION GROUP AG, and Elewout Depicker, VP Commercial and Corporate Development EMEA of Li-Cycle Corp. will be working together in future on the recycling of l